Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Matovit
- Development stage
- Unknown
- Lead developer
- PT SOHO Industri Pharmasi
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Matovit is an oral eye health supplement developed and manufactured by Soho Global Health. It is formulated as a combination of bilberry extract, beta-carotene, retinol (vitamin A), and vitamin E. Matovit is primarily used as a supportive therapy to maintain healthy vision, reduce eye fatigue (asthenopia), and protect ocular tissues from oxidative damage, particularly in individuals at risk of age-related macular degeneration or diabetic retinopathy.
- Brand names
- MatovitMatovit AXMatovit Fifty
Beyond the preview
Go deeper on Matovit.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Matovit.